Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Sunesis Pharmaceuticals |
---|---|
Information provided by: | Sunesis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00607997 |
This study will evaluate the overall remission rate of treatment with SNS 595 Injection in patients at least 60 years of age with previously untreated AML
Condition | Intervention | Phase |
---|---|---|
Leukemia Acute Disease Acute Myeloid Leukemia Nonlymphocytic Leukemia Myelodysplastic Syndromes |
Drug: SNS-595 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2 Open-Label, Multicenter Clinical Study of the Safety and Efficacy of SNS-595 Injection in Patients Equal to or Greater Than 60 Years of Age With Previously Untreated Acute Myeloid Leukemia |
Estimated Enrollment: | 135 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | December 2009 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
All Study Patients: Experimental |
Drug: SNS-595
All patients receive SNS-595 Injection
|
Other objectives of this study include:
Ages Eligible for Study: | 60 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Glenn Michelson, MD | 1-877-767-7672 | clinicaltrials@sunesis.com |
United States, California | |
Scripps Cancer Center | Recruiting |
La Jolla, California, United States, 92037 | |
United States, Colorado | |
Rocky Mountain Blood and Marrow Transplant Program | Recruiting |
Denver, Colorado, United States, 80218 | |
United States, Illinois | |
The University of Chicago | Recruiting |
Chicago, Illinois, United States, 60637 | |
United States, Indiana | |
Indiana University Cancer Center | Recruiting |
Indianapolis, Indiana, United States, 46206 | |
St. Francis Hospital & Health Systems at Beech Grove Campus | Recruiting |
Indianapolis, Indiana, United States, 46237 | |
United States, Kansas | |
Cancer Center of Kansas | Recruiting |
Wichita, Kansas, United States, 67214 | |
Cancer Center of Kansas | Recruiting |
Wichita, Kansas, United States, 67208 | |
United States, Louisiana | |
LSU Health Sciences Center at Shreveport | Recruiting |
Shreveport, Louisiana, United States, 71103 | |
United States, Massachusetts | |
Dana-Farber Cancer Institute | Recruiting |
Boston, Massachusetts, United States, 02115 | |
United States, Minnesota | |
University of Minnesota Physicians BMT Clinic | Recruiting |
Minneapolis, Minnesota, United States, 55455 | |
University of Minnesota Physicians Masonic Cancer Center | Recruiting |
Minneapolis, Minnesota, United States, 55455 | |
University of Minnesota Medical Center, Fairview | Recruiting |
Minneapolis, Minnesota, United States, 55455 | |
United States, Mississippi | |
University of Mississippi Medical Center | Recruiting |
Jackson, Mississippi, United States, 39216 | |
United States, Missouri | |
University of MO Ellis Fischel Cancer Center | Recruiting |
Columbia, Missouri, United States, 65203 | |
United States, Pennsylvania | |
University of Pittsburgh Cancer Institute | Recruiting |
Pittsburgh, Pennsylvania, United States, 15232 | |
United States, South Carolina | |
Hollings Cancer Center at Medical University of South Carolina | Recruiting |
Charleston, South Carolina, United States, 29425 | |
United States, Tennessee | |
Vanderbilt-Ingram Cancer Center | Recruiting |
Nashville, Tennessee, United States, 37232 | |
United States, Texas | |
MD Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
United States, Utah | |
Huntsman Cancer Institute at the University of Utah | Recruiting |
Salt Lake City, Utah, United States, 84112 |
Study Director: | Craig Berman, MD | Sunesis Pharmaceuticals |
Responsible Party: | Sunesis Pharmaceuticals ( Craig Berman, MD-Medical Monitor ) |
Study ID Numbers: | SPO-0014 |
Study First Received: | January 23, 2008 |
Last Updated: | June 2, 2009 |
ClinicalTrials.gov Identifier: | NCT00607997 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Leukemia Myeloid Elderly Hematologic Blood Cancer Malignancy |
SNS-595 Sunesis Hematologic Diseases Myelodysplastic Syndromes Older voreloxin reveal-1 |
Acute Disease Leukemia Acute Myelocytic Leukemia Preleukemia Precancerous Conditions |
Hematologic Diseases Myelodysplastic Syndromes Leukemia, Myeloid Bone Marrow Diseases Leukemia, Myeloid, Acute |
Acute Disease Disease Attributes Disease Neoplasms by Histologic Type Precancerous Conditions Hematologic Diseases Myelodysplastic Syndromes Leukemia, Myeloid |
Leukemia, Myeloid, Acute Leukemia Preleukemia Neoplasms Pathologic Processes Syndrome Bone Marrow Diseases |